The Extraordinary General Meeting in Medivir Aktiebolag (publ) (“Medivir”) on 26 January 2018 resolved, among other things, on the following;
The meeting resolved to authorize the board, for the period up to the annual general meeting 2018, to resolve to issue new shares of series B with deviation from the shareholders’ pre-emptive rights. The total number of shares that may be issued under the authorization shall total not more than 20 percent of the number of shares of series B issued as per the date of the meeting.
The meeting further resolved on an additional issue authorization whereby the board is authorized, for the period up to the annual general meeting 2018, to resolve to issue new shares of series B with pre-emptive rights for the company’s shareholders. The total number of shares that may be issued under the authorization shall be within the limits of the articles of association, as applicable from time to time.
Issuances of new shares under the authorizations shall be made on market terms and conditions. For further details, refer to Medivir’s press release on 2 January 2018.
For further information, please contact:
Erik Björk, CFO Medivir AB, mobile: +46 (0)72 228 2831.
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir is listed on the Nasdaq Stockholm Mid Cap List.